When Glycaemic Control Comes Too Fast: Treatment‐Induced Neuropathy of Diabetes and Charcot Neuro‐Osteoarthropathy as Emerging Iatrogenic Complications of Rapid Metabolic Correction
Dured DardariABSTRACT
Purpose of Review
Diabetes therapeutics can lower glycated haemoglobin (HbA1c) by several percentage points within weeks. While long‐term microvascular risk is reduced by improved glycaemia, abrupt metabolic transitions may destabilise tissues adapted to chronic hyperglycemia. We review treatment‐induced neuropathy of diabetes (TIND) and active Charcot neuro‐osteoarthropathy (CNO) as two neurovascular complications reported after rapid glycaemic correction, and we propose a unifying ‘metabolic tempo’ framework for prevention and early detection.
Recent Findings
TIND is an acute, painful small‐fibre and autonomic neuropathy occurring within 2–8 weeks after large HbA1c reductions, frequently coinciding with early worsening of retinopathy and nephropathy. Human in vivo nerve imaging demonstrates epineurial arteriovenous shunting and proliferative, leaky microvessels, supporting a microvascular dysregulation/ischaemia‐reperfusion model. For CNO, causal evidence linking rapid glycaemic improvement to disease onset remains limited and mainly observational; however, multiple case reports (including pregnancy, post‐transplantation, and major weight loss contexts) and retrospective cohorts suggest that major glycaemic ‘deceleration’ may cluster in the months preceding active CNO in susceptible patients with long‐standing neuropathy.
Summary
Rapid glycaemic correction should not be avoided when urgently needed, but ‘tempo‐aware’ strategies may be warranted in microvascularly fragile patients (very high baseline HbA1c, established neuropathy/retinopathy, kidney disease, or major weight loss). We outline pragmatic risk stratification, surveillance, and interdisciplinary pathways (neurology‐podiatry‐ophthalmology‐nephrology) to reduce delayed diagnosis and prevent deformity and disability.